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loss during anti-tuberculosis therapy in kidney
transplantationTo the Editor,
Rifampin (RFP) is well-known as a strong inducer of CYP3A4
and can lead to rapid turnover of calcineurin inhibitors
(CNIs). Co-prescription of RFP and CNI is a critical issue in
kidney transplantation patients [1]. We report a most dra-
matic case of rapid-onset acute antibody-mediated rejec-
tion (AMR) resulting in rapid graft loss within 1 day,
occurring during anti-tuberculosis (TB) therapy in a kidney
transplant recipient.
A 24-year-old man, diagnosed with immunoglobulin (Ig)A
nephropathy in October 2008, underwent peritoneal dial-
ysis in April 2010. He received a live-donor kidney trans-
plant from his mother in March 2011 with regular
immunosuppressant agents, including mycophenolate
mofetil, tacrolimus, and prednisolone. On November 18,
2014, he came to the emergency room with a chief
complaint of exertional dyspnea for 5 days. The initial vital
signs and the physical examination were unremarkable. The
laboratory data showed a serum creatinine level of
2.34 mg/dL (baseline: 1.8e2.0 mg/dL). Chest X-ray showed
cardiomegaly and right-side pleural effusion. TB was
proved by pericardial biopsy (Figs. 1A and 1B) and he
received anti-TB drugs, consisting of isoniazid 300 mg, RFP
600 mg, ethambutol 1200 mg, and pyrazinamide 1500 mg
daily from December 2, 2014. Decreased urine output was
noted on the next day and serum creatinine increased to
6.8 mg/dL. Renal biopsy was performed and showed severe
acute AMR featuring widespread fibrin thrombosis of the
arterioles and glomerular capillaries associated with com-
plete cortical infarction (Fig. 1CeG). Immunofluorescence
studies showed negative results for IgG, IgA, IgM, and
complement component (C)1q, and only focal weak
equivocal C3 staining in the glomerulus. C4d was positive in
the peritubular capillaries (Fig. 1H), excluding otherConflicts of interest: All authors declare no conflicts of interest.
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disseminated intravascular coagulation, and CNI nephro-
toxicity. The morphology mimics either hyperacute rejec-
tion or accelerated acute rejection. Hemodialysis
treatment commenced. During hospitalization, the dose of
tacrolimus started at 6 mg/d, increased to 8 mg/d on
December 4 for 1 day, and has remained at 4 mg/d since
December 5, 2014 after occurrence of graft loss due to the
acute AMR.
Although interaction between RFP and CNIs has been
well discussed in the literature, the unique aspect of the
current report is that it represents the most dramatic case
of rapid-onset acute AMR concurrent with TB and the
initiation of therapy. The rapid-onset of acute rejection
occurring within 1 day after drug use is unusual. It is
possible that both the immune reaction triggered by TB
itself and the effect of tacrolimus play an important role in
the process. It can also be argued that the rejection was a
process in evolution at the time of TB diagnosis; however,
his renal function, which was relatively stable before the
onset of rejection with creatinine of around 2 mg/dL for
several months, is evidence to support that the process was
not in progress at the time of TB diagnosis. The limitation of
this case report is that the serum tacrolimus level was not
closely monitored and the dose was not increased
accordingly.
The current case re-emphasizes the importance of pre-
vention and treatment of TB infection in kidney trans-
plantation. To avoid reactivation of latent TB infection
after immunosuppressive therapy, diagnosis, and treatment
of latent TB are strongly recommended during the pre-
transplantation period [1]. To treat active TB infection
after transplantation, RFP should be avoided [2], and use of
RFP-sparing protocols is highly suggested [3]. Although pre-
existing TB is deemed a contraindication to trans-
plantation, several reports have demonstrated that pre-y Elsevier Taiwan LLC. All rights reserved.
Figure 1. Pericardial tuberculosis showing necrotizing granuloma (A; H&E stain) with acid-fast bacillus (B; acid-fast stain). Renal
biopsy showing severe acute antibody-mediated rejection mimicking hyperacute rejection featuring widespread fibrin thrombosis
(D; H&E stain) of the arterioles and glomerular capillaries associated with interstitial hemorrhage (C, white arrow; H&E stain) and
neutrophil infiltrate (C, black arrow; H&E stain), with complete cortical infarction (C). Intravascular and intraglomerular throm-
bosis highlighted by periodic Schiffemethenamine silver stain (E), phosphotungstic acidehematoxylin fibrin stain (F) and CD61
immunohistochemistry stain indicating the presence of platelets (G). Linear staining of C4d immunoreactivity along inner surface of
peritubular capillary, characteristic of antibody-mediated rejection (H). Clinical course during the hospitalization (I). The tacro-
limus dose was increased from 6 mg/d initially to 8 mg/d on December 2, 2014 for 1 day, and kept at 4 mg/d from December 5,
2014. H&E Z hematoxylin and eosin.
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managed successfully [4]. If RFP is prescribed, increase in
the dose of CNI, and close monitoring of the trough CNI
level is essential. The dose of tacrolimus should be
increased (even to 2e10 times of the original doses) based
on serum levels of tacrolimus in patients receiving RFP
therapy [5].
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